• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Seasonal influenza vaccine and Guillain-Barr? syndrome: A self-controlled case series study

tetano

Editor, Senior Moderator
Neurology. 2020 Feb 25. pii: 10.1212/WNL.0000000000009180. doi: 10.1212/WNL.0000000000009180. [Epub ahead of print] [h=1]Seasonal influenza vaccine and Guillain-Barr? syndrome: A self-controlled case series study.[/h]
Grave C[SUP]1[/SUP], Boucheron P[SUP]2[/SUP], Rudant J[SUP]2[/SUP], Mikaeloff Y[SUP]2[/SUP], Tubert-Bitter P[SUP]2[/SUP], Escolano S[SUP]2[/SUP], Hocine MN[SUP]2[/SUP], Coste J[SUP]2[/SUP], Weill A[SUP]2[/SUP].
[h=3]Author information[/h]

[h=3]Abstract[/h] [h=4]OBJECTIVE:[/h] To evaluate the risk of Guillain-Barr? syndrome (GBS) following seasonal influenza vaccination based on French nationwide data.
[h=4]METHODS:[/h] All cases of GBS occurring in metropolitan France between September 1 and March 31 from 2010 to 2014 were identified from the French national health data system. Data were analyzed according to the self-controlled case series method. The risk period started 1 day after the patient received vaccine (D1) until 42 days after vaccination (D42). The incidence of GBS during this risk period was compared to that of the control period (D43-March 31). The incidence rate ratio (IRR) was estimated after adjusting for seasonality and presence or not of acute infections.
[h=4]RESULTS:[/h] Between September and March, of the 2010/2011 to 2013/2014 influenza vaccination seasons, 3,523 cases of GBS occurred in metropolitan France and were included in the study. Among them, 15% (527 patients) had received influenza vaccination. A total of 140 patients developed GBS during the 42 days following influenza vaccination. The crude risk of developing GBS was not significantly increased during the 42 days following influenza vaccination (IRR, 1.02; 95% confidence interval [CI], 0.83-1.25; p = 0.85). This result remained nonsignificant after adjustment for calendar months and the incidence of acute gastrointestinal and respiratory tract infections (IRR, 1.10; 95% CI, 0.89-1.37; p = 0.38). In contrast, the risk of GBS was fourfold higher after acute respiratory tract infection (IRR, 3.89; 95% CI, 3.52-4.30; p < 0.0001) or gastrointestinal infection (IRR, 3.64; 95% CI, 3.01-4.40; p < 0.0001).
[h=4]CONCLUSIONS:[/h] No association between seasonal influenza vaccination and GBS was shown during the 42 days following vaccination.
? 2020 American Academy of Neurology.


PMID: 32098853 DOI: 10.1212/WNL.0000000000009180
 
Back
Top Bottom